More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$257806323
EPS
-0.63
P/E ratio
--
Price to sales
108.71
Dividend yield
--
Beta
0.766607
Previous close
$0.81
Today's open
$0.80
Day's range
$0.74 - $0.82
52 week range
$0.74 - $4.46
show more
CEO
David Chang
Employees
152
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
346467307
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript
Allogene Therapeutics, Inc. ( ALLO ) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases November 9, 2026 9:00 AM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Conference Call Participants Vivek Nagaraja Biren Amin - Piper Sandler & Co., Research Division Tyler Van Buren - TD Cowen, Research Division John Newman - Canaccord Genuity Corp., Research Division Cha Cha Yang - Jefferies LLC, Research Division Presentation Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Conference Call.
Seeking Alpha • Nov 9, 2026

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced preliminary safety, efficacy and translational data from the ongoing Phase 1 RESOLUTION study evaluating ALLO-329, an investigational, next-generation, off-the-shelf allogeneic CAR T product designed specifically for autoimmune disease. The data are being presented today at the American College of Rheumatology (ACR) Convergence in Orlando, Florida.
GlobeNewsWire • Nov 9, 2026

Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Geoffrey Parker Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Michael Yee - UBS Investment Bank, Research Division Jiale Song - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Jack Allen - Robert W.
Seeking Alpha • Nov 6, 2026

Allogene Therapeutics Q3 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 6, 2026

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company's participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.
GlobeNewsWire • Nov 3, 2026

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.
GlobeNewsWire • Oct 29, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026.
GlobeNewsWire • Oct 26, 2026

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Sep 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Allogene Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.